Functional characterization of mutant genes associated with autosomal dominant familial hypercholesterolemia: Integration and evolution of genetic diagnosis

M. D. Di Taranto, M. N. D'Agostino, G. Fortunato

Research output: Contribution to journalArticle

Abstract

Aims: Familial Hypercholesterolemia (FH) is one of the most frequent dyslipidemias, the autosomal dominant form of which is primarily caused by mutations in the LDL receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin type 9 (PCSK9) genes, although in around 20% of patients the genetic cause remains unidentified. Genetic testing has notably improved the identification of patients suffering from FH, the most frequent cause of which is the presence of mutations in the LDLR gene. Although more than 1200 different mutations have been identified in this gene, about 80% are recognized to be pathogenic. We aim to overview the current methods used to perform the functional characterization of mutations causing FH and to highlight the conditions requiring a functional characterization of the variant in order to obtain a diagnostic report. Data synthesis: In the current review, we summarize the different types of functional assays - including their advantages and disadvantages - performed to characterize mutations in the LDLR, APOB and PCSK9 genes helping to better define their pathogenic role. We describe the evaluation of splicing alterations and two major procedures for functional characterization: 1. ex vivo methods, using cells from FH patients; 2. in vitro methods using cell lines. Conclusions: Functional characterization of the LDLR, APOB and PCSK9 mutant genes associated with FH can be considered a necessary integration of its genetic diagnosis.

Original languageEnglish
Pages (from-to)979-987
Number of pages9
JournalNutrition, Metabolism and Cardiovascular Diseases
Volume25
Issue number11
DOIs
Publication statusPublished - 2015

Fingerprint

Hyperlipoproteinemia Type II
Molecular Evolution
LDL Receptors
Apolipoproteins B
Mutation
Genes
Genetic Testing
Dyslipidemias
Cell Line
Proprotein Convertase 9

Keywords

  • APOB
  • Diagnostic tools
  • Familial hypercholesterolemia
  • Functional assay
  • LDLR
  • Mutation pathogenicity
  • PCSK9

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

Functional characterization of mutant genes associated with autosomal dominant familial hypercholesterolemia : Integration and evolution of genetic diagnosis. / Di Taranto, M. D.; D'Agostino, M. N.; Fortunato, G.

In: Nutrition, Metabolism and Cardiovascular Diseases, Vol. 25, No. 11, 2015, p. 979-987.

Research output: Contribution to journalArticle

@article{55b1c144fd4a478a8998027cae2a6001,
title = "Functional characterization of mutant genes associated with autosomal dominant familial hypercholesterolemia: Integration and evolution of genetic diagnosis",
abstract = "Aims: Familial Hypercholesterolemia (FH) is one of the most frequent dyslipidemias, the autosomal dominant form of which is primarily caused by mutations in the LDL receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin type 9 (PCSK9) genes, although in around 20{\%} of patients the genetic cause remains unidentified. Genetic testing has notably improved the identification of patients suffering from FH, the most frequent cause of which is the presence of mutations in the LDLR gene. Although more than 1200 different mutations have been identified in this gene, about 80{\%} are recognized to be pathogenic. We aim to overview the current methods used to perform the functional characterization of mutations causing FH and to highlight the conditions requiring a functional characterization of the variant in order to obtain a diagnostic report. Data synthesis: In the current review, we summarize the different types of functional assays - including their advantages and disadvantages - performed to characterize mutations in the LDLR, APOB and PCSK9 genes helping to better define their pathogenic role. We describe the evaluation of splicing alterations and two major procedures for functional characterization: 1. ex vivo methods, using cells from FH patients; 2. in vitro methods using cell lines. Conclusions: Functional characterization of the LDLR, APOB and PCSK9 mutant genes associated with FH can be considered a necessary integration of its genetic diagnosis.",
keywords = "APOB, Diagnostic tools, Familial hypercholesterolemia, Functional assay, LDLR, Mutation pathogenicity, PCSK9",
author = "{Di Taranto}, {M. D.} and D'Agostino, {M. N.} and G. Fortunato",
year = "2015",
doi = "10.1016/j.numecd.2015.06.007",
language = "English",
volume = "25",
pages = "979--987",
journal = "Nutrition, Metabolism and Cardiovascular Diseases",
issn = "0939-4753",
publisher = "Elsevier B.V.",
number = "11",

}

TY - JOUR

T1 - Functional characterization of mutant genes associated with autosomal dominant familial hypercholesterolemia

T2 - Integration and evolution of genetic diagnosis

AU - Di Taranto, M. D.

AU - D'Agostino, M. N.

AU - Fortunato, G.

PY - 2015

Y1 - 2015

N2 - Aims: Familial Hypercholesterolemia (FH) is one of the most frequent dyslipidemias, the autosomal dominant form of which is primarily caused by mutations in the LDL receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin type 9 (PCSK9) genes, although in around 20% of patients the genetic cause remains unidentified. Genetic testing has notably improved the identification of patients suffering from FH, the most frequent cause of which is the presence of mutations in the LDLR gene. Although more than 1200 different mutations have been identified in this gene, about 80% are recognized to be pathogenic. We aim to overview the current methods used to perform the functional characterization of mutations causing FH and to highlight the conditions requiring a functional characterization of the variant in order to obtain a diagnostic report. Data synthesis: In the current review, we summarize the different types of functional assays - including their advantages and disadvantages - performed to characterize mutations in the LDLR, APOB and PCSK9 genes helping to better define their pathogenic role. We describe the evaluation of splicing alterations and two major procedures for functional characterization: 1. ex vivo methods, using cells from FH patients; 2. in vitro methods using cell lines. Conclusions: Functional characterization of the LDLR, APOB and PCSK9 mutant genes associated with FH can be considered a necessary integration of its genetic diagnosis.

AB - Aims: Familial Hypercholesterolemia (FH) is one of the most frequent dyslipidemias, the autosomal dominant form of which is primarily caused by mutations in the LDL receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin type 9 (PCSK9) genes, although in around 20% of patients the genetic cause remains unidentified. Genetic testing has notably improved the identification of patients suffering from FH, the most frequent cause of which is the presence of mutations in the LDLR gene. Although more than 1200 different mutations have been identified in this gene, about 80% are recognized to be pathogenic. We aim to overview the current methods used to perform the functional characterization of mutations causing FH and to highlight the conditions requiring a functional characterization of the variant in order to obtain a diagnostic report. Data synthesis: In the current review, we summarize the different types of functional assays - including their advantages and disadvantages - performed to characterize mutations in the LDLR, APOB and PCSK9 genes helping to better define their pathogenic role. We describe the evaluation of splicing alterations and two major procedures for functional characterization: 1. ex vivo methods, using cells from FH patients; 2. in vitro methods using cell lines. Conclusions: Functional characterization of the LDLR, APOB and PCSK9 mutant genes associated with FH can be considered a necessary integration of its genetic diagnosis.

KW - APOB

KW - Diagnostic tools

KW - Familial hypercholesterolemia

KW - Functional assay

KW - LDLR

KW - Mutation pathogenicity

KW - PCSK9

UR - http://www.scopus.com/inward/record.url?scp=84960495405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960495405&partnerID=8YFLogxK

U2 - 10.1016/j.numecd.2015.06.007

DO - 10.1016/j.numecd.2015.06.007

M3 - Article

C2 - 26165249

AN - SCOPUS:84960495405

VL - 25

SP - 979

EP - 987

JO - Nutrition, Metabolism and Cardiovascular Diseases

JF - Nutrition, Metabolism and Cardiovascular Diseases

SN - 0939-4753

IS - 11

ER -